1 / 5

Addressing Product Selection Issues in Global Fund PSM Plans and Procurement Challenges

This document examines critical issues surrounding the product selection process within Global Fund (GF) Procurement and Supply Management (PSM) plans. It discusses the potential revision of medicine lists post-approval, the introduction of opportunistic infection (OI) drugs, and the revision of guidelines for antiretrovirals (ARVs). Key topics include understanding the approval process from GF, procurement requirements for condoms, responding to World Bank (WB) requirements, and challenges with paediatric ARV formulations. The document aims to clarify these complex processes for stakeholders involved in global health initiatives.

yanni
Download Presentation

Addressing Product Selection Issues in Global Fund PSM Plans and Procurement Challenges

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Working group Product selection issues

  2. GF PSM Plans • Can the list of medicines be revised once PSM plans have been approved? • Introduction of OI drugs (SA) • revision of guidelines (EG) • latency period with needs in additional ARVs and before guidelines be up-dated • What is the process to get the approval from GF? LFA, PR, Port-Folio?

  3. Condoms procurement requirements • Clarification needed on WB requirements (Tanzania) • How countries in the room have responded to WB requirements of a pre qualified list of manufacturers ?

  4. ARV paediatrics • WHO Pre-qualified list: too few paediatric formulations (Uganda) • Not registered at country level

  5. Other issues • GF: notion of stringent authorities (SA) • Clinton Foundation: match between the pricing list and WHO pre-qualified list

More Related